当前位置: X-MOL首页 › SCI期刊查询及投稿分析系统 › Nuclear Medicine and Biology杂志
Nuclear Medicine and Biology
基本信息
期刊名称 | Nuclear Medicine and Biology NUCL MED BIOL |
---|---|
期刊ISSN | 0969-8051 |
期刊官方网站 | https://www.sciencedirect.com/journal/nuclear-medicine-and-biology |
是否OA | No |
出版商 | Elsevier Inc. |
出版周期 | Bimonthly |
文章处理费 | 登录后查看 |
始发年份 | 1993 |
年文章数 | 38 |
影响因子 | 3.6(2023) scijournal影响因子 greensci影响因子 |
中科院SCI期刊分区
大类学科 | 小类学科 | Top | 综述 |
---|---|---|---|
医学3区 | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学3区 | 否 | 否 |
CiteScore
CiteScore排名 | CiteScore | SJR | SNIP | ||
---|---|---|---|---|---|
学科 | 排名 | 百分位 | 6.0 | 0.658 | 0.787 |
Medicine Radiology, Nuclear Medicine and Imaging |
71/333 | 78% |
|||
Biochemistry, Genetics and Molecular Biology Cancer Research |
107/230 | 53% |
|||
Biochemistry, Genetics and Molecular Biology Molecular Medicine |
89/178 | 50% |
补充信息
自引率 | 5.6% |
---|---|
H-index | 82 |
SCI收录状况 | Science Citation Index Expanded |
官方审稿时间 | 登录后查看 |
网友分享审稿时间 | 数据统计中,敬请期待。 |
接受率 | 登录后查看 |
PubMed Central (PMC) | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0969-8051%5BISSN%5D |
投稿指南
期刊投稿网址 | https://www.editorialmanager.com/NUCMEDBIO |
---|---|
收稿范围 | Official Journal of the Society of Radiopharmaceutical Sciences Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science for imaging as well as therapeutic applications. More specifically the synthesis (automated and manual), in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy of new radiopharmaceuticals. Translational studies of novel targeted radiopharmaceuticals, e.g. first in human use, are warmly welcomed. In addition, in vivo imaging studies using radioactive tracers for physiological and pathophysiological research or drug discovery support are welcome. In all cases, the importance of the target to an unmet clinical need should be the first consideration. These multidisciplinary studies should validate the mechanism of localization whether the tracer is based on binding to a receptor, enzyme, antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the tracer to changes in disease or treatment, although studies validating mechanism alone are acceptable as well. In the case of therapeutic radiopharmaceuticals, the specificity of labeled compound localization and therapeutic effect should be addressed. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized and should provide a substantial improvement over existing methodologies. Articles related to radiopharmacy, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, are also welcome if the article provides a significant impact on the field. |
收录体裁 | |
投稿指南 | https://www.sciencedirect.com/journal/nuclear-medicine-and-biology/publish/guide-for-authors |
投稿模板 | |
参考文献格式 | https://www.elsevier.com/journals/nuclear-medicine-and-biology/0969-8051/guide-for-authors |
编辑信息 |
|
我要分享 (欢迎您来完善期刊的资料,分享您的实际投稿经验)